CD8A and neoplasm: In contrast to other treatment groups, PeptiBAC-Trp2 in combination with anti-PD-1-treated tumors had significantly more tumor-infiltrating CD4+ and CD8+ T cells as well as Trp2-specific CD8+ T cells, indicating an enhanced effect on T cell responses by combining the two treatment modalities (figure 5B, upper panel).